Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Chetan Jeurkar, DO, Benjamin E Leiby, PhD, Joshua Banks, MS, Margaret Kasner, MDMSc, Gina Keiffer, MD, Lindsay Wilde, MD, Joanne Filicko-O'Hara, MD, Neil Palmisiano, MDMS

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-133837

Published: 2020

Journal Articles

High Survival in Patients with Myelofibrosis Undergoing a Two-Step Approach to Hematopoietic Stem Cell Transplantation (HSCT): Effects of Donor Source and Pre-HSCT Splenic Therapy on Outcomes

Shaik Rashid, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, John L. Wagner, MD, William O'Hara, PharmD, Usama Gergis, MD, Neal Flomenberg, MD, Dolores Grosso, DNP, CRNP

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-139630

Published: 2020

Journal Articles

Vaccination Response after Autologous Stem Cell Transplantation

Onder Alpdogan, MD, Jennifer Hong, MD, Thomas R. Klumpp, MD, Abdullateef O Abdulkareem, MD MPH, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Dolores Grosso, DNP, CRNP, Margaret Kasner, MDMSc, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Lindsay Wilde, MD, Pierluigi Porcu, MD, Usama Gergis, MD, John L. Wagner, MD, Neal Flomenberg, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141269

Published: 2020

Journal Articles

Encouraging Results of Haploidentical Transplantation in Older Patents Using the Two-Step T Cell Tolerization Platform - Results of a Prospective Trial

Dolores Grosso, DNP, CRNP, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, John L. Wagner, MD, William O'Hara, PharmD, Shaik Rashid, MD, Gina Mateja, BA, Usama Gergis, MD, Neal Flomenberg, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-136377

Published: 2020

Journal Articles

The Two-Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation (HI HSCT): 15 Years of Transplants in Patients 19-78 Years Old

Dolores Grosso, DNP, CRNP, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, John L. Wagner, MD, William O'Hara, PharmD, Shaik Rashid, MD, Usama Gergis, MD, Neal Flomenberg, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139866

Published: 2020

Journal Articles

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Lindsay Wilde, MD, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, John L. Wagner, MD, Onder Alpdogan, MD, Margaret Kasner, MDMSc, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Gina Keiffer, MD, Dolores Grosso, DNP, CRNP, Michael Millenson, Amy R. MacKenzie, MD, Allison Zibelli, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Usama Gergis, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140719

Published: 2020

Journal Articles

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Jonathan Pan, MD, Sushil Ghimire, MD, Tingting Zhan, PhD, Onder Alpdogan, MD, Andrew E. Chapman, DO, Matthew Carabasi, MD, Ubaldo Martinez-Outschoorn, MD, Lewis J. Rose, MD, Michael Ramirez, MD, John L Wagner, MD, Barbara Pro, MD, Mark A. Weiss, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD

Blood (2019) 134 (Supplement_1): 5318.

https://doi.org/10.1182/blood-2019-125836

Published: 2019

Journal Articles

2 Step Myeloablative Haploidentical Transplant (HI MA HSCT) in Intermediate and High-Risk Patients-Changing the Timing of the 2 Step Approach

Dolores Grosso, DNP, CRNP, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MD, William O'Hara, PharmD, John L Wagner, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD

Blood (2018) 132 (Supplement 1): 4661.

https://doi.org/10.1182/blood-2018-99-110815

Published: 2018

Journal Articles

HSCT Engraftment Kinetics: Differences in Chimerism between Haploidentical (HI) and Matched Related (MR) Transplant Recipients (HSCT) after the 2 Step Approach

Dolores Grosso, DNP, CRNP, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MD, Pierluigi Porcu, MD, William O'Hara, PharmD, John L Wagner, MD, Neal Flomenberg, MD

Blood (2018) 132 (Supplement 1): 3371.

https://doi.org/10.1182/blood-2018-99-117364

Published: 2018

Journal Articles

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Neil Palmisiano, MD, Grace Jeschke, PhD, Lindsay Wilde, MD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 4267.

https://doi.org/10.1182/blood.V130.Suppl_1.4267.4267

Published: 2017

Journal Articles

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

Neil Palmisiano, MD, Grace Jeschke, PhD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 3858.

https://doi.org/10.1182/blood.V130.Suppl_1.3858.3858

Published: 2017

Journal Articles

Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial

Jakub Svoboda, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stefan Klaus Barta, MDMRCP,MS, Nadia Khan, MD, Henry C. Fung, FRCP,MBBChir, Carlyn Rose Tan, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Lauren Elizabeth Strelec, BA, Sarah J. Nagle, Steven M. Bair, MD, Sheryl Mitnick, MPH, RN, Terease S. Waite, PhD RN, MBE, Rachel Lynn Sargent, MD, Agata M. Bogusz, MDPhD, Ziver Sahin, MD, Anthony R. Mato, MD, Stephen J. Schuster, MD

Blood (2017) 130 (Supplement 1): 191.

https://doi.org/10.1182/blood.V130.Suppl_1.191.191

Published: 2017

Journal Articles

The Presence of Recipient CMV Immunodominant Human Leukocyte Antigen (HLA) Alleles Affect Outcomes after Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

Dolores Grosso, DNP, CRNP, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, William O'Hara, PharmD, Neil Palmisiano, MD, John L. Wagner, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD

Blood (2017) 130 (Supplement 1): 1959.

https://doi.org/10.1182/blood.V130.Suppl_1.1959.1959

Published: 2017

Journal Articles

Differences in Allogeneic Product T-Cell Subsets According to Donor Age: Associations with Immune Reconstitution and Acute Graft Versus Host Disease (aGVHD) in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

Jason Chen, MD, Jonathan Pan, MD, John L. Wagner, MD, Michael Sun, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas Klumpp, MD, Neil Palmisiano, MD, Ubaldo Martinez-Outschoorn, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Dolores Grosso, DNP, CRNP

Blood (2017) 130 (Supplement 1): 3200.

https://doi.org/10.1182/blood.V130.Suppl_1.3200.3200

Published: 2017

Journal Articles

Moderate Reduction in LVEF Is Associated with an Increased Risk of Post-HSCT Symptomatic Cardiomyopathy

Kinjal Parikh, MD, Lekha Mikkilineni, MD, Fern Martin, MD, Dolores Grosso, R.N., CRNP, DNP, Benjamin Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, Manish Sharma, MD, Mark Weiss, MD, John L. Wagner, MD, Neal Flomenberg, MD, Joanne Filicko-O'Hara, MD

Blood (2015) 126 (23): 2023.

https://doi.org/10.1182/blood.V126.23.2023.2023

Published: 2015

Journal Articles

Creatinine > 1.5 Mg/Dl and MDS Diagnosis Predicts Poor Outcome Following HSCT

Fern Martin, MD, Lekha Mikkilineni, MD, Kinjal Parikh, MD, Dolores Grosso, DNP, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Manish Sharma, MD, Mark Weiss, MD, John L. Wagner, MD, Neal Flomenberg, MD, Joanne Filicko-O'Hara, MD

Blood (2015) 126 (23): 3220.

https://doi.org/10.1182/blood.V126.23.3220.3220

Published: 2015

Journal Articles

Clinical Outcomes of 2-Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Effects of CD34 Stem Cell Dose in the Setting of a Consistent T-Cell Dose

Sameh Gaballa, MD, Neil D. Palmisiano, MD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Margaret Kasner, MD, Ubaldo Martinez, MD, John L. Wagner, MD, Mark Weiss, MD, Neal Flomenberg, MD, Dolores Grosso, DNP

Blood (2014) 124 (21): 1212.

https://doi.org/10.1182/blood.V124.21.1212.1212

Published: 2014

Journal Articles

CD3/8 T-Cell Responses to CMV Reactivation in Patients Undergoing Haploidentical Transplants: A Retrospective Analysis

Mahasweta Gooptu, MD, Benjamin Leiby, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez, MD, Barbara Pro, MD, Manish Sharma, MD, John L. Wagner, MD, Mark Weiss, MD, Neal Flomenberg, MD, Dolores Grosso, DNP

Blood (2014) 124 (21): 1170.

https://doi.org/10.1182/blood.V124.21.1170.1170

Published: 2014

Journal Articles

The Addition Of Bortezomib (Velcade®) To The Combination Of Mitoxantrone and Etoposide For Relapsed Or Refractory Acute Leukemia Does Not Appear To Improve The Likelihood Of Response: Results Of a Phase II Trial

Neil D. Palmisiano, MD, Sameh Gaballa, MD, Bijoyesh Mookerjee, MD, John L. Wagner, MD, Margaret Kasner, MD, Matthew Carabasi, MD, Onder Alpdogan, MD, Ubaldo Martinez, MD, Mark Weiss, MD, Neal Flomenberg, MD, Joanne Filicko-O'Hara, MD

Blood (2013) 122 (21): 2689.

https://doi.org/10.1182/blood.V122.21.2689.2689

Published: 2013

Journal Articles

A 2 Step Approach To Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Low Non-Relapse Related Mortality (NRM) and High Overall Survival (OS) Rates Confirmed In Second Generation Trial

Dolores Grosso, DNP, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Margaret Kasner, MD, Ubaldo Martinez, MD, William O'Hara, PharmD, John L. Wagner, MD, Mark Weiss, MD, Neal Flomenberg, MD

Blood (2013) 122 (21): 3360.

https://doi.org/10.1182/blood.V122.21.3360.3360

Published: 2013

NARROW

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

High Survival in Patients with Myelofibrosis Undergoing a Two-Step Approach to Hematopoietic Stem Cell Transplantation (HSCT): Effects of Donor Source and Pre-HSCT Splenic Therapy on Outcomes

Vaccination Response after Autologous Stem Cell Transplantation

Encouraging Results of Haploidentical Transplantation in Older Patents Using the Two-Step T Cell Tolerization Platform - Results of a Prospective Trial

The Two-Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation (HI HSCT): 15 Years of Transplants in Patients 19-78 Years Old

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

2 Step Myeloablative Haploidentical Transplant (HI MA HSCT) in Intermediate and High-Risk Patients-Changing the Timing of the 2 Step Approach

HSCT Engraftment Kinetics: Differences in Chimerism between Haploidentical (HI) and Matched Related (MR) Transplant Recipients (HSCT) after the 2 Step Approach

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial

The Presence of Recipient CMV Immunodominant Human Leukocyte Antigen (HLA) Alleles Affect Outcomes after Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

Differences in Allogeneic Product T-Cell Subsets According to Donor Age: Associations with Immune Reconstitution and Acute Graft Versus Host Disease (aGVHD) in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

Moderate Reduction in LVEF Is Associated with an Increased Risk of Post-HSCT Symptomatic Cardiomyopathy

Creatinine > 1.5 Mg/Dl and MDS Diagnosis Predicts Poor Outcome Following HSCT

Clinical Outcomes of 2-Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Effects of CD34 Stem Cell Dose in the Setting of a Consistent T-Cell Dose

CD3/8 T-Cell Responses to CMV Reactivation in Patients Undergoing Haploidentical Transplants: A Retrospective Analysis

The Addition Of Bortezomib (Velcade®) To The Combination Of Mitoxantrone and Etoposide For Relapsed Or Refractory Acute Leukemia Does Not Appear To Improve The Likelihood Of Response: Results Of a Phase II Trial

A 2 Step Approach To Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Low Non-Relapse Related Mortality (NRM) and High Overall Survival (OS) Rates Confirmed In Second Generation Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only